Dr. Kosaraju is the CEO and President of Phare Bio, a social venture using AI and deep learning to develop novel classes of antibiotics in partnership with Jim Collins’ lab at MIT. Phare is a recipient of TED’s Audacious Project to support powerful solutions to the world’s most urgent challenges, and an Advanced Research Project Agency for Health (ARPA-H) funding award.

Dr. Kosaraju has spent her career building companies and driving innovation in infectious disease and computational biology. She was founding CEO of Variant Bio, a venture-backed company specializing in genomics and therapeutic development, and an executive with SIGA Technologies, an antiviral drug developer that successfully advanced antiviral drug candidates to market. During her tenure, SIGA achieved FDA approval for a novel smallpox antiviral and worked in partnership with the CDC, BARDA and DoD to deliver 2 million courses to the US Strategic National Stockpile. Dr. Kosaraju was a White House appointee in the Pentagon, serving as the Special Assistant to the Assistant Secretary of Defense for Health Affairs. In this capacity, she provided executive leadership in the management of a $50 billion Military Health System that included healthcare for military service members, biodefense, and international humanitarian assistance.

She received the Office of the Secretary of Defense Medal for Exceptional Public Service, the highest non-career civilian honor given within the Department of Defense. She is a Member of the Council on Foreign Relations, co-founded the Alliance to End Biological Threats, and is a Lecturer at Stanford’s Center for Biosecurity and Pandemic Resilience. She received her M.D. from Columbia University College of Physicians and Surgeons and her B.A. in Human Biology from Stanford University.